Physician profile
Damien M Benjamin
NPI 1407881055
$578.27
in general payments reported to CMS, 2019-2025
14 companies · $69.52 in 2025
The $69.52 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2021: $12.86 · 2022: $67.47 · 2023: $46.79 · 2024: $203 · 2025: $69.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $166.19 | 2019 | |
| Janssen Biotech, INC. | $78.06 | 2022-2024 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $68.43 | 2024-2025 | Ibsrela |
| Conmed Corporation | $54.72 | 2024 | Airseal |
| Takeda Pharmaceuticals U.S.A., INC. | $53.34 | 2024-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.02 | 2022-2023 | Trulance |
| Gilead Sciences, INC. | $20.62 | 2023 | Veklury |
| Phathom Pharmaceuticals, INC. | $19.46 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $19.06 | 2024 | Dupixent |
| Madrigal Pharmaceuticals | $17.26 | 2025 | Rezdiffra |
| Genzyme Corporation | $15.57 | 2022 | |
| Hologic INC | $12.86 | 2021 | |
| Kci USA, INC. | $12.48 | 2019 | |
| Organon LLC | $11.20 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damien Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.